Please login to the form below

Not currently logged in
Email:
Password:

Trophos SA Awarded $1.4mn research grant

Agence Nationale pour la Recherche, the French research agency, has awarded Trophos SA a $1.4mn research grant to support drug development.

Agence Nationale pour la Recherche (ANR), the French research agency, has awarded Trophos SA a $1.4mn research grant to support drug development.

Biopharmaceutical company Trophos SA is currently heading a project into the efficacy of candidate drug TRO40303.

The research project, which is called IRIstop, is hoping to evaluate the ability of TRO40303 to curb cellular damage that occurs in cardiac and cerebral ischemia-reperfusion injury.

CEO at Trophos, Antoine Beret, said: "We are very pleased that the ANR has chosen to support the preclinical and clinical development of TRO40303 as a potential treatment for cardiac and cerebral ischemia-reperfusion injury."

Professor Alain Berdeaux of the University of Creteil's Institut Mondor de Recherche Biomedicale, and Professor Michael Plotkine of the Paris Descartes, Faculte de sciences pharmaceutiques et biologiques will be collaborating on project IRIstop.

Compounds contained within TRO40303 have been found to stimulate function and survival of neurons, cardiomyocytes, and hepatocytes.

Beret said: "This would be the second Trophos product to enter the clinic with a mitochondria-based mechanism of action that is predicted to exhibit a therapeutic benefit in diseases such as neuropathic pain, ischemia-reperfusion injury, and hepatotoxicity."

28th February 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics